Some information on this website may be viewed only by healthcare professionals.
If you would like to enter this section then please register as a healthcare professional.
Dr Falk Pharma UK Ltd Privacy Policy can be found here.
Please note that our privacy policy has recently been updated. Click here to review the policy.
Leading the way in gastroenterology and metabolic disease
Access to expert education, events and resources for gastro and metabolic diseases is limited. It’s challenging to stay on top of the continual advancements in this field so we’ve developed THE DR FALK WAY
Innovative and reliable treatments for gastroenterology and metabolic diseases
Inflammatory Bowel Disease (IBD) is a term mainly used to describe three conditions namely Ulcerative Colitis, Crohn’s Disease and Microscopic Colitis. These are chronic conditions that involve inflammation of the gastrointestinal tract. MC is the most recently recognised condition to be classed as IBD and it has become increasingly recognised over the last few years as a common condition.
The incidence of liver diseases in the developed world has increased significantly over the past decades. Dr Falk Pharma focuses on autoimmune liver diseases such as Primary Biliary Cholangitis, Autoimmune Hepatitis and Primary Sclerosing Cholangitis. These diseases have chronic clinical courses and if left untreated can lead to serious consequences such as liver cirrhosis and death.
EoE is a chronic and progressive inflammatory disease which affects the lining of the oesophagus. Originally referred to as asthma of the oesophagus, EoE is thought to be triggered by an allergic response, usually to food but possibly also to environmental or other factors.
We believe that by creating a strong community. Together we know more, together we do more.
Available on your computer, tablet and mobile
We are delighted to welcome you to the 101st Falk Forum at the Royal College of General Practitioners, 30 Euston Square, London. This special event welcomes key opinion leaders from across the UK and Europe..
We cordially invite you to attend the second symposium of the Falk Foundation Experimental Hepatology Days in Lyon. After the big success of our first Symposium 2023 in Zürich, we are very pleased to bring..
In this meeting, we uniquely bring together scientists, clinicians and patients to explore the mucosal immunology of inflammatory bowel disease (IBD) through the lens of the Montreal classification of IBD, which assesses age at diagnosis,..
